Bharat Petroleum Corporation has given a downward sloping trendline breakout at Rs 400 which was also the immediate acting resistance in the stock and went on to make a high of Rs 411.50 on a closing basis.
The stock is witnessing high volume along with the support placed at 20 and 50-days SMA. The momentum indicators are also signaling a positive probability towards the bullish momentum in the stock.
We are recommending buying the stock in the rangeof Rs 408-400with targetat Rs 430-437and stop lossof Rs 391with return of 7 percent.
Disclaimer: The author is Head-Technical & Derivative Research, Axis Securities. The views and investment tips expressed by investment experts on moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Best Tech Stocks To Invest In 2019: Brooks Automation Inc.(BRKS)
- [By Joseph Griffin]
Brooks Automation (NASDAQ:BRKS) insider Maurice H. Tenney sold 8,969 shares of Brooks Automation stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $29.80, for a total transaction of $267,276.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
- [By Shane Hupp]
Shares of Brooks Automation, Inc (NASDAQ:BRKS) have been assigned an average recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $34.00.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Brooks Automation (BRKS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
BNP Paribas Arbitrage SA reduced its stake in Brooks Automation, Inc (NASDAQ:BRKS) by 21.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,761 shares of the semiconductor company’s stock after selling 6,086 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Brooks Automation were worth $616,000 at the end of the most recent reporting period.
Best Tech Stocks To Invest In 2019: Adaptimmune Therapeutics plc(ADAP)
- [By Logan Wallace]
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
Get Adaptimmune Therapeutics alerts:
Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) to Post -$0.28 Earnings Per Share (americanbankingnews.com) Peritoneal Cancer Market Pipeline Review H1- Target Drug Profile, Top Industry Intelligence, Major Key Players and … (thefreenewsman.com) Escherichia coli Infections Market Research Report Pipeline Review H1 Assessment by Mechanism of Action, Drug … (theperfectinvestor.com) Adaptimmune Therapeutics plc (ADAP): Do You Have This Stock in Portfolio?: (bitcoinpriceupdate.review)
Several equities analysts have weighed in on the company. Leerink Swann reissued an “outperform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, March 15th. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday. SunTrust Banks increased their target price on Adaptimmune Therapeutics to $18.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.94.
- [By ]
Adaptimmune Therapeutics (ADAP) : “If you’ve speculated on this one, you’ve won. Let’s move on.”
Icahn Enterprises (IEP) : “I don’t really know what they own so I can’t recommend it.”
- [By Ethan Ryder]
Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.
- [By ]
Cramer was bearish on Chesapeake Energy (CHK) , Adaptimmune Therapeutics (ADAP) , Icahn Enterprises (IEP) , Bristol-Myers Squibb (BMY) , Quad/Graphics (QUAD) , Spectra Energy Partners (SEP) and L Brands (LB) .
Best Tech Stocks To Invest In 2019: Schwab US Large-Cap ETF (SCHX)
- [By Ethan Ryder]
Milestone Group Inc. decreased its stake in Schwab US Large-Cap ETF (NYSEARCA:SCHX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,425 shares of the company’s stock after selling 2,710 shares during the period. Schwab US Large-Cap ETF makes up 0.7% of Milestone Group Inc.’s investment portfolio, making the stock its 19th largest holding. Milestone Group Inc.’s holdings in Schwab US Large-Cap ETF were worth $4,001,000 as of its most recent filing with the Securities & Exchange Commission.